FARMINGDALE, N.Y.--(BUSINESS WIRE)--Jan. 14, 1999--The Board of Directors of Misonix, Inc. ["Misonix"] (Nasdaq: MSON) today announced that it had authorized the repurchase by the Company of up to 300,000 of its Common Shares, constituting approximately 5% of its shares on a fully diluted basis.
Such shares would be subject to purchase, from time to time, by private negotiation or open market purchase.
Michael A. McManus, Jr., Chief Executive Officer, stated that, in view of the present price of the Company's shares, the Board viewed it as being in the best interest of the Company and its stockholders to authorize such repurchase.
Misonix, Inc. develops, manufactures, and/or markets medical, scientific, and industrial ultrasonic and air pollution systems.
Forward Looking Statements: Statements in this news release looking forward in time are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties, including general economic conditions, delays and risks associated with the performance of contracts, potential acquisitions, consumer and industry acceptance, litigation and regulatory risks.
CONTACT:
Misonix, Inc., Farmingdale
Michael A. McManus, Jr., President and CEO, 516/694-9555
--------------------------------------------------------------------------------
|
